Alexandra advises on a wide range of commercial matters, with a particular focus on IP and technology-rich sectors such as life sciences/healthcare, consumer/retail and TMT.
Alexandra regularly advises on complex commercial arrangements in these sectors including collaboration agreements, licensing deals, manufacturing and supply arrangements and distribution agreements. Alexandra also advises on non-contentious intellectual property matters, including IP aspects of M&A and corporate transactions and other arrangements for the exploitation of IP, and information technology and service provision arrangements.
Expertise
Industries
Experience
Representative matters
Life Sciences
Reckitt on the proposed sale of its E45 brand and related sub-brands to Karo Pharma for an implied enterprise value of GBP200m.
Grünenthal on its USD922m acquisition from AstraZeneca of prescription products Nexium in Europe and Vimovo worldwide (excluding the U.S. and Japan).
Grünenthal on the acquisition of the European business of Crestor™ (rosuvastatin) and associated second brands (excluding the UK and Spain) from AstraZeneca.
Pro bono
Mentoring young people through A&O’s award-winning Smart Start programme.
Advising a UK schools charity in relation to agreements with certain corporate partners.
Qualifications
Admissions
Admitted as a Solicitor (England and Wales), 2013
Academic
LPC, College of Law, 2011
LLB, Law, University of Warwick, 2009
Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.